Ascendis Pharma A/S (NASDAQ:ASND) Sets New 12-Month High – Still a Buy?

Shares of Ascendis Pharma A/S (NASDAQ:ASND) hit a new 52-week high during mid-day trading on Monday . The company traded as high as $208.16 and last traded at $204.50, with a volume of 38815 shares. The stock had previously closed at $205.91.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on ASND shares. Cantor Fitzgerald upped their price target on Ascendis Pharma A/S from $200.00 to $203.00 and gave the stock an “overweight” rating in a research report on Friday, August 8th. Wedbush upped their target price on Ascendis Pharma A/S from $212.00 to $220.00 and gave the company an “outperform” rating in a research report on Friday, August 8th. Stifel Nicolaus upped their target price on Ascendis Pharma A/S from $212.00 to $254.00 and gave the company a “buy” rating in a research report on Friday, August 8th. Morgan Stanley began coverage on Ascendis Pharma A/S in a research report on Thursday, July 3rd. They issued an “overweight” rating and a $250.00 target price on the stock. Finally, UBS Group reissued a “buy” rating and issued a $307.00 target price (up from $306.00) on shares of Ascendis Pharma A/S in a research report on Friday, August 8th. Fifteen equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $244.36.

Ascendis Pharma A/S Trading Down 0.6%

The firm has a 50-day simple moving average of $182.68 and a two-hundred day simple moving average of $168.05. The company has a market capitalization of $12.53 billion, a price-to-earnings ratio of -39.55 and a beta of 0.39.

Ascendis Pharma A/S (NASDAQ:ASND) last issued its quarterly earnings results on Thursday, August 7th. The biotechnology company reported ($0.93) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.42) by $0.49. The company had revenue of $216.28 million during the quarter, compared to analysts’ expectations of $163.17 million. Equities research analysts anticipate that Ascendis Pharma A/S will post -4.34 EPS for the current year.

Institutional Trading of Ascendis Pharma A/S

Several institutional investors have recently added to or reduced their stakes in ASND. Rhumbline Advisers increased its holdings in Ascendis Pharma A/S by 4.0% in the 2nd quarter. Rhumbline Advisers now owns 1,441 shares of the biotechnology company’s stock valued at $249,000 after purchasing an additional 55 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its stake in shares of Ascendis Pharma A/S by 0.6% in the second quarter. China Universal Asset Management Co. Ltd. now owns 12,186 shares of the biotechnology company’s stock worth $2,103,000 after acquiring an additional 73 shares in the last quarter. Main Management ETF Advisors LLC grew its stake in shares of Ascendis Pharma A/S by 1.7% during the second quarter. Main Management ETF Advisors LLC now owns 5,864 shares of the biotechnology company’s stock worth $1,012,000 after purchasing an additional 96 shares in the last quarter. Gilbert & Cook Inc. grew its stake in shares of Ascendis Pharma A/S by 2.0% during the second quarter. Gilbert & Cook Inc. now owns 6,750 shares of the biotechnology company’s stock worth $1,165,000 after purchasing an additional 131 shares in the last quarter. Finally, Chicago Partners Investment Group LLC lifted its position in Ascendis Pharma A/S by 4.5% in the second quarter. Chicago Partners Investment Group LLC now owns 3,732 shares of the biotechnology company’s stock valued at $635,000 after acquiring an additional 161 shares during the last quarter.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.